Hims & Hers misses revenue estimates as strategy shift hits sales

Hims & Hers reported Q1 revenue of $608.1 million, missing the $616.85 million consensus, and posted a surprise loss of 40 cents per share versus expectations for a 4-cent profit. The company raised full-year revenue guidance to $2.8 billion-$3.0 billion from $2.7 billion-$2.9 billion and projected Q2 revenue of $680 million-$700 million, but margins were pressured by the shift to branded GLP-1 drugs and write-downs tied to compounded semaglutide ingredients. Shares fell more than 12% after hours as investors weighed stronger guidance against legal, regulatory and profitability concerns.

Analysis

The market is treating this as a margin miss, but the more important signal is that HIMS is being forced to migrate from an asset-light, quasi-arbitrage model into a more regulated distribution layer with lower take rates. That transition can lift top-line quality over time, but near term it compresses unit economics because branded-drug economics are structurally less forgiving than compounded supply. The write-downs suggest management is still cleaning up the old model while trying to reprice the new one, which usually means 1-2 quarters of noisy gross margin prints before the mix stabilizes.

The bigger second-order effect is competitive. A credible Novo relationship gives HIMS legitimacy, but it also reduces the differentiation that supported its premium multiple; if the product becomes more standardized, customer acquisition and retention will matter more than novelty. That should pressure other telehealth platforms and DTC subscription names with similar “convenience” economics, while helping NVO by expanding route-to-market without having to build a consumer funnel itself.

The key catalyst path is regulatory, not operational. If FDA pressure on compounding eases, HIMS gets optionality on peptides and broader category expansion; if it tightens further, the company likely faces another step-down in growth quality and possible legal overhang. In the next 30-90 days, the stock will trade on whether investors believe the raised revenue guide is real organic acceleration or just acquisition-driven arithmetic; consensus likely underestimates how much of the valuation now depends on proving sustainable contribution margin, not revenue growth alone.

Contrarian view: the selloff may be overdone if investors are assuming the margin reset is permanent. If HIMS can show that branded GLP-1 traffic converts into higher lifetime value and lower churn, the current drawdown could create a tradable entry ahead of a cleaner 2H narrative. The risk is that the market starts to value HIMS like a regulated pharmacy intermediary rather than a high-growth consumer platform, which would justify a materially lower multiple even if revenue guidance keeps rising.

Key Decisions for Investors

• Short HIMS on strength over the next 1-3 weeks into any post-earnings bounce; target a retracement toward pre-guidance levels if gross margin remains pressured. Risk: if management proves conversion and retention improve, the stock can re-rate quickly on momentum.
• Pairs trade: long NVO / short HIMS for 1-3 months. Thesis: NVO monetizes distribution and brand without taking consumer acquisition risk, while HIMS bears execution and regulatory risk. Cover if HIMS demonstrates sustained margin stabilization or if Novo partnership economics appear more accretive than expected.
• Buy HIMS put spreads 1-2 quarters out to express downside from another margin-reset or regulatory headline. Prefer defined risk because a positive FDA/pipeline update could squeeze the stock sharply.
• For a higher-conviction relative value expression, long NVO against a basket of DTC healthcare names with exposed compounding or subscription economics. The market may be underpricing how much regulatory scrutiny will compress multiples across the group.
• Set a catalyst watch for the next quarterly print: if HIMS revenue beats but EBITDA/gross margin do not inflect, treat any rally as a fade opportunity rather than a trend reversal.